ReviewiScience2026
The dual role of BRD9 in cancer: Mechanistic insights and therapeutic prospects.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bromodomain-containing protein 9 (BRD9), an essential subunit of the switch/sucrose non-fermentable (SWI/SNF) remodeling complex, functions as a chromatin reader that recognizes acetylated lysine (Kac) residues to modulate chromatin structure and gene expression. Dysregulated BRD9 contributes to cancer cell proliferation, metastasis, and drug resistance, making it a promising therapeutic target. However, BRD9 also exerts a tumor-suppressive function in a context-dependent manner. A comprehensive elucidation of the ambivalent role and underlying mechanism of BRD9 in oncogenesis is urgently needed. In this review, we present a detailed overview of the current knowledge regarding the structure, dysregulation, and biological functions of BRD9 in cancer. We then systematically summarize the oncogenic roles and tumor-suppressive functions of BRD9 in different contexts. Finally, we explore the potential of BRD9 as an innovative therapeutic target and discuss its implications in clinical oncology, providing insights into emerging directions for novel cancer treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.